Business Description
Mezzion Pharma Co
ISIN : KR7140410002
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 56.18 | |||||
Equity-to-Asset | 0.71 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.11 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 22.64 | |||||
Beneish M-Score | -1.76 | |||||
WACC vs ROIC |
Growth Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 0.7 | |||||
3-Year EBITDA Growth Rate | 4.1 | |||||
3-Year EPS without NRI Growth Rate | 5.5 | |||||
3-Year FCF Growth Rate | -11.2 | |||||
3-Year Book Growth Rate | -0.9 |
Momentum Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 47.27 | |||||
9-Day RSI | 49.29 | |||||
14-Day RSI | 48.27 | |||||
6-1 Month Momentum % | -24.11 | |||||
12-1 Month Momentum % | -16.67 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.65 | |||||
Quick Ratio | 2.39 | |||||
Cash Ratio | 1.91 | |||||
Days Inventory | 139.42 | |||||
Days Sales Outstanding | 40.66 | |||||
Days Payable | 69.95 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3.5 | |||||
Shareholder Yield % | 0.19 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 15.93 | |||||
Operating Margin % | -75.16 | |||||
Net Margin % | -43.8 | |||||
FCF Margin % | -130 | |||||
ROE % | -14.54 | |||||
ROA % | -10.09 | |||||
ROIC % | -41.82 | |||||
ROC (Joel Greenblatt) % | -232.78 | |||||
ROCE % | -13.02 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 43.7 | |||||
PB Ratio | 16.19 | |||||
Price-to-Tangible-Book | 23.15 | |||||
EV-to-EBIT | -104.93 | |||||
EV-to-EBITDA | -124.55 | |||||
EV-to-Revenue | 42.04 | |||||
EV-to-FCF | -33.14 | |||||
Price-to-Median-PS-Value | 1.2 | |||||
Price-to-Net-Current-Asset-Value | 25.85 | |||||
Price-to-Net-Cash | 47.65 | |||||
Earnings Yield (Greenblatt) % | -0.95 | |||||
FCF Yield % | -2.95 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Mezzion Pharma Co Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil â‚©) | 20,246.024 | ||
EPS (TTM) (â‚©) | -307 | ||
Beta | 0.75 | ||
Volatility % | 34.51 | ||
14-Day RSI | 48.27 | ||
14-Day ATR (â‚©) | 1261.406138 | ||
20-Day SMA (â‚©) | 29550 | ||
12-1 Month Momentum % | -16.67 | ||
52-Week Range (â‚©) | 27000 - 50200 | ||
Shares Outstanding (Mil) | 29.82 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Mezzion Pharma Co Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Mezzion Pharma Co Stock Events
Event | Date | Price(â‚©) | ||
---|---|---|---|---|
No Event Data |
Mezzion Pharma Co Frequently Asked Questions
What is Mezzion Pharma Co(XKRX:140410)'s stock price today?
When is next earnings date of Mezzion Pharma Co(XKRX:140410)?
Does Mezzion Pharma Co(XKRX:140410) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |